CWA Asset Management Group LLC Makes New $399,000 Investment in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

CWA Asset Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the fourth quarter, Holdings Channel.com reports. The firm purchased 44,389 shares of the biotechnology company’s stock, valued at approximately $399,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. CWM LLC lifted its position in shares of Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 8,180 shares during the period. FMR LLC increased its stake in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at about $84,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 10,700 shares in the last quarter. Finally, PFG Investments LLC boosted its position in shares of Aurinia Pharmaceuticals by 37.9% during the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 7,900 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares in the company, valued at $112,591.08. This represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $8.34 on Thursday. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -55.60 and a beta of 1.24. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The firm’s 50-day simple moving average is $8.69 and its 200 day simple moving average is $7.19.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AUPH shares. StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.